Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO

Breath-Powered Intranasal Sumatriptan Dry Powder

(2016) Deborah Tepper   HEADACHE

A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine

(2015) Roger Cady   Expert Opinion on Drug Delivery

The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine

(2015) Roger Cady   EXPERT OPINION ON PHARMACOTHERAPY

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks

(2015) Stewart J. Tepper et al.   HEADACHE

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)

(2014) Roger K. Cady et al.   HEADACHE

What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study

(2014) Antonia F. H. Smelt et al.   PLoS One

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder

(2013) Mohammad Obaidi et al.   HEADACHE

Breath Powered Nasal Delivery: A New Route to Rapid Headache Relief

(2013) Per G. Djupesland et al.   HEADACHE

Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice

(2012) Luana Lionetto et al.   EXPERT OPINION ON PHARMACOTHERAPY

Changes in liquid emptying in migraine patients: diagnosed with liquid phase gastric emptying scintigraphy

(2012) H. Yalcin et al.   INTERNAL MEDICINE JOURNAL